France's IMPLANET H1 revenue rises on medical equipment strength, US growth

By Reuters News


Overview

  • France medical implants maker's H1 revenue rose 23% yr/yr to €7.1 mln

  • Gross margin improved by 7 points to 59.5%, driven by JSS system and US growth

  • Operating loss narrowed by 13% despite higher commercial investments


Outlook

  • IMPLANET plans to reinforce its U.S. commercial team and accelerate JAZZ rollout

  • Company aims to expand JAZZ platform distribution in China with Sanyou Medical

  • IMPLANET intends to launch SMTP Quntas ultrasonic scalpels for surgical revision and tumor surgery


Result Drivers

  • JSS SYSTEM SALES - Co said strong performance of new JSS hybrid posterior fixation system drove spine implant revenue, with associated sales doubling yr/yr

  • MEDICAL EQUIPMENT GROWTH - Co said continued rollout of medical equipment distribution, notably SMTP ultrasonic scalpel, lifted segment revenue 27% yr/yr

  • US EXPANSION - Co said US revenue rose 54% yr/yr, driven by strong JSS system sales and expanded commercial activities


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

EUR 7.1 mln

H1 Net Loss

EUR 2.14 mln

H1 Operating Income

-EUR 1.87 mln


Reuters Recommended Reads

  • Sept 15 - UK's IP Group HY26 NAV/share rises on Pfizer obesity programme progress

  • Sept 14 - Kestra Medical Technologies Q1 revenue beats estimates, raises FY revenue outlook

  • Sept 14 - Hain Celestial Q4 sales miss estimates on divestiture impact


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.